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ORIGINAL ARTICLE
Background/Aims: Metabolic syndrome is an emerging risk factor for cardiovascular disease. This study
investigated the prevalence of metabolic syndrome among psychiatric patients in order to identify the dominant
factors of metabolic syndrome. 
Methods: We enrolled 225 patients who had been admitted to a chronic psychiatric hospital from October 2005
to February 2006. The prevalence of metabolic syndrome was assessed based on the Adult Treatment Panel
(ATP)-III with the new criterion of waist circumference in the Asia-Pacific Region.   
Results: The study population was relatively young (41.1 ± 8.8 years) and obese (waist in men, 91.3 ± 9.2 cm;
waist in women, 84.1 ± 8.8 cm). Sixty percent of patients met the waist criterion of metabolic syndrome and 56%
met the low high density lipoprotein (HDL) criterion. The mean serum triglycerides were high (170.0 ± 119.7 mg/dL)
and 46% of patients met the triglyceride criterion. In contrast, less than 10% of patients showed impaired fasting
glucose or high blood pressure (5%, 9%, respectively). The overall prevalence of metabolic syndrome was
34.2% by applying ATP-III criteria (40% in men and 20% in women, respectively). No specific anti-psychotic
drugs were related to significant increase in the incidence of metabolic syndrome.  
Conclusions: Abdominal obesity and dyslipidemia (low HDL and high triglycerides) were dominant contributing
factors of metabolic syndrome among psychiatric patients, and the affected age groups were relatively young. These
findings indicate that active and early screening, including triglycerides, HDL, and waist measurement, are absolutely
essential to managing metabolic syndrome in psychiatric patients. (Korean J Intern Med 2010;25:168-173)
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INTRODUCTION
The prevalence of metabolic syndrome has increased
among general populations due to the increasing tendency
of less physical activity, high caloric diet and resultant
obesity. Such metabolic issues are also of importance for
psychiatric patients. Metabolic syndrome is a composition
of several metabolic derangements that originate from
insulin resistance [1]. It is well known that metabolic
syndrome increases cardiovascular morbidity and
mortality. Medical conditions in psychiatric patients are
often underestimated, which can lead psychiatric patients
to be more susceptible to medical morbidity [2]. In fact,
cardiovascular disease is one of the most important
medical conditions among psychiatric patients [3]. There
are several explanations as to why psychiatric patients
are susceptible to cardiovascular disease. An inactive
lifestyle and poor dietary choices make psychiatric patients
obese, and the side effects of antipsychotic agents have
received attention [4-6]. Several reports on the prevalence
of metabolic syndrome among psychiatric patients have
been published [7-11]. However, there is little information
on non-caucasian patients or on the characteristics of
their metabolic syndrome. We therefore investigated theKim SH, et al. Obesity and dyslipidemia in psychiatrics    169
metabolic profiles that contribute to the development of
metabolic syndrome in Korean patients.
METHODS
We identified 249 consecutive patients who had been
admitted to a chronic psychiatric hospital from October
2005 to February 2006. Basic physical measurements,
such as weight, height and abdominal circumference
were checked in all patients upon admission. Routine
medical tests were also performed, such as complete
blood cell count, chemistry, urinalysis, chest X-ray, and
electrocardiogram. We included 225 patients diagnosed
as having psychiatric disease, and who were on antipsy-
chotic agents, and conducted examinations for metabolic
syndrome components. The Institutional Review Board
of the National Cancer Center of Korea approved this
study. Written informed consent was not required for
this retrospective study. 
The prevalence of metabolic syndrome was assessed
based on the Adult Treatment Panel (ATP)-III. In addition,
we used the new criterion of waist circumference in the
Asia-Pacific Region instead of the original one [12]. The
modified definition required more than three of the
following: 1) increased waist circumference (> 90 cm in
men and > 80 cm in women), 2) high triglycerides (≥
150 mg/dL), 3) low high density lipoprotein (HDL)
cholesterol (< 40 mg/dL in men and < 50 mg/dL in women),
4) high blood pressure (≥ 130 / 85 mmHg or currently
on antihypertensive medication), and 5) high fasting
glucose (≥ 110 mg/dL or currently on antidiabetic
medication). Serum total cholesterol, HDL cholesterol
and triglycerides were measured by enzymatic colorimetric
assay using an autoanalyzer (Hitachi 7600, Hitachi Ltd.,
Tokyo, Japan). Means and standard deviations were
used to present continuous variables, and frequency
counts were used to present categorical variables. Any
drugs taken for longer than three months were also
investigated. Each patient group of antipsychotic agents
was compared on the basis of metabolic syndrome preva-
lence. Similarly, the associations between categorical
parameters were assessed using the chi-square test or
Fisher’s exact test. Continuous variables were presented
as the mean ± standard deviation and were compared by
student t test. Statistical significance was accepted at a
two-tailed p < 0.05. Stata/SE for Windows (Stata Corp.,
College Station, TX, USA) was used for analysis.
RESULTS
The clinical and metabolic characteristics of the subjects
are given in Table 1. The mean age of the subjects was 41.4
years. The patients were relatively young compared to the
mean age of those in a previous study that investigated
metabolic syndrome in the same ethnic general population
[13]. The subjects were obese, according to waist circum-
ference (91.3 ± 9.1 cm in men, 84.1 ± 8.8 cm in women),
weight (70.5 ± 12.0 kg), and body mass index (BMI) (26.1
± 3.4 kg/m2). Their triglyceride levels were high (170.0 ±
119.7 mg/dL). The prevalence of diabetes and hypertension
was 8.4% and 4.4%, respectively. Psychiatric diagnoses
varied and schizophrenia was dominant: schizophrenia
72.0%, depression 12.9%, delusional disorder 6.7%,
compulsive disorder 3.1%, personality disorder with
psychotic feature 2.7%, bipolar disorder 2.7%. Overall, the
distribution of antipsychotic agents taken for longer than
three months was risperidone 45%, haloperidol 32.5%,
chloropromazine 12.5%, olanzapine 11.7%, amisulpiride
6.7%, aripiprazole 6.7%, and clozapine 5%. More than half
of the patients had been taking the same antipsychotic
drugs during the last six months as a characteristic of
chronic hospitalization. There were no significant differences
between each group’s prevalence of metabolic syndrome
with Fisher’s exact test (Table 2). The overall prevalence of
metabolic syndrome was 34.2%. The men were more
susceptible to metabolic syndrome than women (40% vs.
20%, respectively). The prevalence of metabolic syndrome
Table 1. Clinical and metabolic characteristics of the
subjects
Characteristics Total (n = 225)
Age, yr  41.1 ± 8.8
Height, cm  164.1 ± 8.3
Weight, kg  70.5 ± 12.0
BMI, kg/m2 26.1 ± 3.4
Waist, cm  89.2 ± 9.6
Fasting glucose, mg/dL  84.2 ± 14.7
Total cholesterol, mg/dL  184.2 ± 36.3
HDL cholesterol, mg/dL  42.2 ± 12.9
Triglycerides, mg/dL  170.0 ± 119.7
LDL cholesterol, mg/dL  109.1 ± 31.5
Systolic BP, mmHg  111.4 ± 11.9
Diastolic BP, mmHg  72.3 ± 9.7
Values are presented as the mean ± SD.
BMI, body mass index; HDL, high density lipoprotein; LDL, low
density lipoprotein; BP, blood pressure.in young men was much higher than the prevalence
reported previously for the general population, and it was
also higher than the prevalence in an older group in the
Korean population (Fig. 1) [13]. The high prevalence of
metabolic syndrome may be attributed to abdominal obesity
and dyslipidemia characterized by high triglycerides and
low HDL cholesterol (Table 3). More than half of all
subjects met the criterion of abdominal obesity (60.0%)
and dyslipidemia (46.2% of patients had high triglycerides
and 56.0% had low HDL cholesterol). In contrast, the
prevalence of high blood pressure and impaired fasting
glucose in the overall population were relatively low (8.9%
and 5.3%, respectively). The prevalence of each metabolic
syndrome component is depicted in Fig. 2. To clarify the
factors contributing to metabolic syndrome, we compared
each component of metabolic syndrome between subjects
who met the criterion with those who did not. Greater
abdominal obesity, higher triglycerides, and lower HDL
cholesterol were prominent in the metabolic syndrome
group (Fig. 3). The difference in mean low density lipoprotein
(LDL) cholesterol levels was not statistically significant.
DISCUSSION
Psychiatric patients showed a high prevalence of
metabolic syndrome because of their high vulnerability to
abdominal obesity and dyslipidemia (high triglycerides
and low HDL cholesterol) as opposed to high blood pressure
and impaired fasting glucose (Fig. 2). A plausible
explanation is that metabolic derangement caused by
Table 2. Correlation of the prevalence of metabolic
syndrome and antipsychotic drugs
Drug Metabolic syndrome p value
Yes No
Chloropromazine Yes 6 9 0.78
No 71 139
Valproic acid Yes 14 20 0.43
No 63 128
Risperidone Yes 22 32 0.25
No 55 116
Haloperidol Yes 11 28 0.46
No 66 120
Olanzapine Yes 6 8 0.56
No 70 140
Lithium Yes 7 9 0.42
No 70 139
Clozapine Yes 0 6 0.10
No 77 142
Amisulpride Yes 3 5 1.00
No 74 143
Aripiprazole Yes 0 8 0.05
No 77 140
Quetiapine Yes 2 2 0.61
No 75 146
Sulpiride Yes 4 2 0.18
No 73 146
Values are presented as numbers.
A p values was calculated by Fisher’s exact test because there
were small values (less 5).
No specific drug was revealed as affecting metabolic syndrome.
Figure 1. Age-specific prevalence of metabolic syndrome (MS)
from 30 to 59 by sex. Data for ages 20 to 29 and over 60 are not
shown due to low values (less than 10). ap < 0.05 between men
and women.
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Figure 2. Prevalence of each metabolic syndrome component.
Values are presented as the percentage of subjects who met
each criterion. TG, triglycerides; HDL, high density lipoprotein;
BP, blood pressure.
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Figure 3. Box plots presenting the distribution of each component of metabolic syndrome. The median of each component is
represented by the horizontal line in the middle of each box. Each box represents the 25 to 75 percent quartiles. The ends of the
vertical lines indicate the minimum and maximum data values except outliers, which are represented as dots outside the line.
Abdominal obesity (A), high triglycerides (B), and low HDL (C) are more prominent than other components (D, E, and F) among the
metabolic syndrome group. MS, metabolic syndrome group; Non-MS, no metabolic syndrome group; HDL, high density lipoprotein;
SBP, systolic blood pressure; DBP, diastolic blood pressure.
Table 3. Prevalence of metabolic syndrome and its components by age (by NCEP ATP-III criteria)
Age, yr Abdominal obesity High TG Low HDL High BP High FBG
Men Women Men Women Men Women Men Women Men Women
All 56.9 67.7 55.6 23.1 61.3 43.1 8.1 10.8 6.3 3.1
20 to 29 20.0 83.3 30.0 0.0 40.0 0.0 40.0 0.0 0.0 0.0
30 to 39 59.7 56.5 64.2 21.7 68.7 47.8 7.5 4.3 6.0 0.0
40 to 49 60.0 66.7 52.7 25.0 58.2 50.0 5.5 8.3 3.6 8.3
50 to 59 54.2 80.0 54.2 20.0 58.3 30.0 4.2 40.0 16.7 0.0
≥ 60 50.0 100.0 0.0 100.0 100.0 100.0 0.0 0.0 0.0 0.0
Values are presented as number. 
NCEP, National Cholesterol Eduication Program; ATP, Adult Treatment Panel; TG, triglycerides; HDL, high density lipoprotein; BP,
blood pressure; FBG, fasting blood glucose. 172 The Korean Journal of Internal Medicine Vol. 25, No. 2, June 2010
physical inactivity or adverse effects of drugs may have
affected abnormal fat distribution or impaired lipid
metabolism rather than elevating blood pressure or
increasing insulin resistance. These characteristics in
psychiatric patients are different from those of other Asian
populations, in which high blood pressure and abdominal
obesity were dominant contributing factors to metabolic
syndrome [14]. Furthermore, this unique combination of
components leading to metabolic syndrome has not been
observed among the general Korean population [13]. In
addition, the underestimation of metabolic syndrome is
problematic, considering that only total cholesterol, fasting
blood glucose, blood pressure, and weight are checked in
usual practice. The screening of waist circumference and
the whole lipid profile, including triglycerides and HDL
cholesterol, could be helpful in detecting metabolic
syndrome among psychiatric patients.  Furthermore, the
prevalence of metabolic syndrome in younger people was
not lower than that in older people (Fig. 1). This means
that they are exposed to complications of metabolic
syndrome, such as cardiovascular disease, over their
lifetime. Therefore, careful attention should be paid to
metabolic disturbances of psychiatric patients. 
Our study has some limitations. There may be insufficient
statistical power, due to the small sample size. In addition,
the study was performed retrospectively, so it was limited
in its ability to confirm the exact prevalence of metabolic
syndrome. However, the present study was conducted in
hospitalized patients at a chronic hospital and the patients
had been hospitalized, on average, for more than 18
months; thus, their lifestyles were relatively uniform and
much more regular and controlled than those of outpatients.
Lifestyle, including physical activity and diet, are
important compounding factors in the study of metabolic
syndrome. Such a controlled lifestyle in our study population
is a strong point. In spite of the controlled lifestyle, the
prevalence of metabolic syndrome was high, so it can be
speculated that general psychiatric outpatients are more
vulnerable to metabolic syndrome than the present
population, and that more active screening and management
should be added to lifestyle modification. 
In conclusion, we found unique characteristics of meta-
bolic syndrome among psychiatric patients. Specifically,
abdominal obesity and dyslipidemia, i.e., low HDL
cholesterol and high triglycerides, are dominant contributing
factors. In addition, the affected ages are younger. These
findings suggest that active and early screening, including
triglycerides, HDL cholesterol, and waist measurement,
are absolutely essential to managing metabolic syndrome
among psychiatric patients.
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